

Interim Financial Statements (Consolidated) for The Year Ended March 31, 2008

November 5 , 2007

Name of Listed Compa	ny: SHIONOGI & CO	., LTD.	Listed Exchanges: Section I of Tokyo	and Osaka	1
Code: 4507			URL <u>http://www.shionogi.co.jp</u>		
Representative:	Title of Person in Charge: President		Name: Motozo Shiono		
Contact responsibility:	Title of Person in Charge: General Mar Public Relati		Name: Noriyuki Kishida	TEL:	(06) 6202-2161
Date of the filing of sen	niannual securities report (scheduled):	December 7,	2007		
Starting date of dividen	d payment (scheduled) :	December 3	2007		

(Note: All amounts are rounded down to the nearest million yen.) 1. Consolidated results for the period from April 1, 2007 to September 30, 2007

(1) Results of operations	(% of change from the corresponding figures for the same interim period of the previous year)						
	Net sales		Operating income	Ordinary income	Net income		
	Million yen	%	Million yen %	Million yen %	Million yen %		
Six months ended September 30, 2007	104,167 13.	.0	17,145 56.1	17,150 56.2	10,788 68.7		
Six months ended September 30, 2006	92,154 (4.	.9)	10,984 (9.6)	10,977 (11.1)	6,394 (23.1)		
Year ended March 31, 2007	199,759 1.	.7	28,863 (1.2)	28,113 (5.2)	18,594 (18.2)		

	Earnings per share	Earnings per share (diluted)
	yen	yen
Six months ended September 30, 2007	31.70	_
Six months ended September 30, 2006	18 . 78	-
Year ended March 31, 2007	54 . 61	-
Defense Fruits in lesses of offiliates	Civ manuflue and ad Cant	amaham 20 2007. (200) m

Reference: Equity in losses of affiliates:

Six months ended September 30, 2007: Six months ended September 30, 2006: Year ended March 31, 2007: (288) million yen (662) million yen (1,100) million yen

(2) Financial position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	yen
As of September 30, 2007	420,361	346,475	82.4	1,018 . 49
As of September 30, 2006	425,155	339,358	79.8	995 . 78
As of March 31, 2007	429,569	345,752	80.4	1,014 . 73
Reference:Shareholders' equity	As of September 30, 2 As of September 30, 2 As of March 31, 2007:	006: 339,090 million ye	en	

(3) Cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of the period
	Million yen	Million yen	Million yen	Million yen
Six months ended September 30, 2007	9,178	(8,598)	(4,081)	71,131
Six months ended September 30, 2006	2,175	(20,957)	(3,916)	53,390
Year ended March 31, 2007	14,115	(8,418)	(7,180)	74,546

2. Dividends

		Cash dividends per share	
(Date of record)	Interim	Year-end	Annual
	yen	yen	yen
Year ended March 31, 2007	8.00	8.00	16.00
Year ending March 31, 2008 (Acutual)	10 . 00		20.00
Year ending March 31, 2008 (Forecast)		10 . 00	20.00

3. Forecasted consolidated results for the year ending March 31, 2008 (April 1, 2007 to March 31, 2008)

(% of change from previous year)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
For the year ending March 31, 2008	Million yen %	Million yen %	Million yen %	Million yen %	yen
	215,000 7.6	40,000 38.6	40,000 42.3	24,000 29.1	70 . 61

4. Others

(1)Significant changes to consolidated subsidiaries during the fiscal year: None

(2)Changes in the accounting principles, procedure, and indication method regarding the preparation of interim consolidated financial statement a) Changes and amendments of accounting standards : Yes

b) Other changes : None

Note: For details, please see page 17 "Changes in basic of presentation of interim consolidated financial statements "

(3)Number of shares issued (common stock)

a) Number of shares outstanding (including treasury stock)	As of September 30, 2007	351,136,165 shares
	As of September 30, 2006	351,136,165 shares
	As of March 31, 2007	351,136,165 shares
b) Treasury stock	As of September 30, 2007	11,233,815 shares
	As of September 30, 2006	10,609,787 shares
	As of March 31, 2007	10,683,759 shares
Note: For details, please see page 25 "Notes to amounts pe	ar sharo"	

Note: For details, please see page 25 "Notes to amounts per share".

(Reference) Summary non-consolidated results

1. Non-consolidated results for the period from April 1, 2007 to September 30, 2007

(1) Results of operations	of change from the o	correspondi	ing figures for the s	ame interin	n period of the prev	ious year)		
	Net sales		Operating income		Ordinary income		Net incor	ne
	Million yen	%	Million y	en %	Million y	en %	Million y	ren %
Six months ended September 30, 2007	96,253	9.4	15,141	66.9	15,958	58.0	9,069	60.4
Six months ended September 30, 2006	88,021	0.5	9,073	(13.2)	10,099	(14.7)	5,653	(33.0)
Year ended March 31, 2007	185,686	1.3	24,893	(3.4)	25,985	(7.6)	17,324	(35.0)

	Earnings per share
	yen
Six months ended September 30, 2007 Six months ended September 30, 2006	26 . 65 16 . 60
Year ended March 31, 2007	50 . 88

(2) Financial position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share		
	Million yen	Million yen	%	yen		
As of September 30, 2007 As of September 30, 2006	405,989 407,521	339,264 334,603	83.6 82.1	998 . 12 982 . 61		
As of March 31, 2007	414,992	340,346	82.0	999 . 69		
Reference: Shareholders' equity As of September 30, 2007: 339,264 million yen						

As of September 30, 2006: 334,603 million yen As of March 31, 2007:

340,346 million yen

2. Forecasted non-consolidated results for the year ending March 31, 2008 (April 1, 2007 to March 31, 2008)

(% of change from previous year)

	Net sales	Operating income Ordinary income		Net income	Earnings per share
	Million yen %	Million yen %	Million yen %	Million yen %	yen
For the year ending March 31, 2008	202,000 8.8	37,000 48.6	38,500 48.2	22,500 29.9	66 . 20

These estimates on November 5, 2007 include a number of assumptions, forward-looking projections and plans. The actual results may Note: differ substantially depending on the situation of competitors, uncertainties in the market. Refer to page 5.

CONTENTS

Results of Operations 4
(1) Analysis of Results of Operations4
(2) Analysis of Financial Position5
(3) Fundamental Policy on Appropriation of Retained Earnings
(4) Business and Other Risks6
Companies in the Shionogi Group7
Management Policy9
(1) Fundamental Management Policy
(2) Management Strategy and Challenges Ahead9
Interim Consolidated Statements of Income 10
Interim Consolidated Balance Sheets 11
Interim Consolidated Statements of Changes in Net Assets
Interim Consolidated Statements of Cash Flows 16
Notes to Interim Consolidated Financial Statements 17
Notes to interim consolidated financial statement
1. Notes to interim consolidated statements of income19
2. Notes to interim consolidated balance sheets 19
3. Notes to interim consolidated statement of changes in net assets 20
4. Notes to interim consolidated statements of cash flow
5. Notes to lease transactions22
6. Notes to securities 23
7. Notes to derivative transactions 23
8. Notes to segment Information24
9. Notes to amounts per share25
Interim Non-consolidated Statements of Income 27
Interim Non-consolidated Balance Sheets 28
Interim Non-consolidated Statement of Changes in Net Assets
Significant accounting policies 33
Notes to interim non-consolidated financial statements
1. Notes to interim non-consolidated statements of income
2. Notes to interim non-consolidated balance sheet35
3. Notes to interim non-consolidated statement of changes in net assets
4. Notes to lease transactions36
5. Notes to securities36
6. Notes to amounts per share37
<u>Others</u> 38
Status of Production, Orders and Sales

Results of Operations

(1) Analysis of Results of Operations

Results for the Six Months Ended September 30, 2007

a) General Overview

In the Japanese pharmaceutical industry during the six months ended September 30, 2007, against the backdrop of discussions on containing rising healthcare costs, the market environment became increasingly severe due to factors including further promotion of use of generic drugs and DRG/PPS (Diagnosis Related Group/Prospective Payment System) for medical expenses. Competition between companies, including global companies, in sales and R&D further intensified, and active business restructuring and consolidation continued.

Under these conditions, the Shionogi Group reviewed its approach to future activities and the targets of its second medium-term management plan (April 2005 to March 2010), which started in 2005, to respond to the severity of the market, and got off to a new start in the third year of the plan. In the area of research and development, Shionogi focused on enhancing its framework for continuously and quickly discovering and developing new world-class drugs and stepped up licensing activities to enhance the development pipeline. In the area of manufacturing, while paying heed to quality and stable supply, Shionogi continued working to cut costs through efforts including ongoing reduction of raw ingredient costs and process improvements. In the area of sales and marketing, market share for the antihyperlipidemia treatment Crestor, on which Shionogi has been concentrating resources, steadily expanded due to support for the drug's efficacy, safety and economy. Moreover, Shionogi further strengthened its efforts to provide accurate information in order to expand its presence in the field of antibacterials, and to relieve the pain and improve the quality of life of cancer patients.

(Units: Millions of yen, S								
	Net sales	Operating income	Ordinary income	Net income				
Six months ended 9/07	104,167	17,145	17,150	10,788				
Six months ended 9/06	92,154	10,984	10,977	6,394				
Percent increase	13.0	56.1	56.2	68.7				

(Illuster Milliane of your O/)

Consolidated Results of Operations

<u>Sales</u>

Sales of prescription drugs increased slightly overall. While sales of Crestor increased significantly, sales of antibiotics declined as a result of the shrinking market and other factors. Royalty income from industrial property rights increased substantially due to an increase in overseas sales of Crestor by AstraZeneca plc. In other businesses, contract manufacturing sales also increased. As a result, net sales totaled ¥104,167 million, an increase of 13.0 percent compared with the same period of the previous fiscal year.

Income

The increase in net sales, particularly the increase in royalty income from industrial property rights, covered the substantial increase in research and development expenses arising from steady progress in R&D activities. As a result, operating income for the six months ended September 30, 2007 increased 56.1 percent compared with the same period of the previous fiscal year to ¥17,145 million, and ordinary income increased 56.2 percent to ¥17,150 million. Net income was ¥10,788 million, an increase of 68.7 percent.

Research and Development

In research and development, Shionogi awaited marketing approval for irbesartan (generic name) for hypertension and pirfenidone (generic name) for idiopathic pulmonary fibrosis. Work progressed on new drugs currently under development, including an antidepressant, an antibacterial, an anti-obesity agent and an antipruritic treatment. In particular, development of anti-obesity and antipruritic treatments is being conducted globally, with Shionogi USA, Inc. as the development base. Johnson & Johnson continued to develop doripenem (generic name), a carbapenem antibiotic that Shionogi out-licensed in the territories of North America and Europe. In October 2007, Johnson & Johnson received an approval for the drug in the United States. Sales of the anti-allergic Claritin are also expected to expand further with the October 2007 approval of an additional pediatric indication for Claritin products as well as addition of dry syrup formulation.

As a result of these activities, research and development expenses for the Shionogi Group during the six months ended September 30, 2007 were ¥19,586 million, equivalent to 18.8 percent of net sales.

Capital Investment

The Shionogi Group's capital investment during the interim period totaled ¥6.1 billion, and centered on expanding manufacturing and research facilities.

b) Segment Information

Pharmaceuticals and Related Businesses

Regarding prescription drugs, sales of Crestor increased as market share steadily expanded. However, overall sales of prescription drugs increased only slightly because sales of existing products such as Flomox, Flumarin and Vancomycin declined due to the shrinking market, increasing use of generic drugs and other factors. In addition, sales of over-the-counter products declined and sales of diagnostics were flat amid intense market competition. On the other hand, contract manufacturing sales, centered on subsidiary Bushu Pharmaceuticals Ltd., increased due to an increase in manufacturing contracts received from outside the Shionogi Group, and royalty income from industrial property rights rose substantially.

As a result, sales of Pharmaceuticals and Related Businesses increased 9.9 percent compared with the same period of the previous fiscal year to ¥99,892 million.

The substantial increase in royalty income from industrial property rights absorbed the increase in research and development expenses. As a result, operating income of Pharmaceuticals and Related Businesses increased 57.9 percent compared with the same period of the previous fiscal year to ¥16,240 million.

Other Businesses

Net sales of Other Businesses increased 234.2 percent compared with the same period of the previous fiscal year to ¥4,275 million due to the increase in contract construction at Shionogi Engineering Service Co., Ltd. Total operating income of Other Businesses increased 29.7 percent to ¥904 million.

(Line the Addition of the second

Forecast for the Year Ending March 31, 2008

Projected results for the year ending March 31, 2008 are as follows.

				(Units: Millions of yen)
	Net sales	Operating income	Ordinary income	Net income
Year ending 3/08	215,000	40,000	40,000	24,000
Year ended 3/07	199,759	28,863	28,113	18,594
Percentage Increase	7.6	38.6	42.3	29.1

Shionogi forecasts that the market environment for prescription drugs will become even more challenging, with continuing strong pressure to reduce spending on health care and the scheduled revision of National Health Insurance (NHI) drug prices in April 2008. Moreover, the business environment of pharmaceutical companies is expected to become even more severe due to factors including rising research and development expenses.

In these conditions, the Shionogi Group will focus on actively implementing its second medium-term management plan, comprising measures aimed at long-term growth centered on its prescription drug business. In particular, in sales and marketing, Shionogi will work to expand market share by concentrating resources on Crestor, Finibax, Avelox and other new products while taking steps to reinforce its sales organization by enhancing activities focused on improving quality of life through alleviation of cancer pain. In research and development, Shionogi will enhance its framework for continuously discovering world-class development compounds. In addition to building an organizational framework for simultaneous development in Japan, the United States and the European Union, Shionogi will strengthen its strategic investment efforts, including aggressive promotion of in-licensing aimed at enhancing the development pipeline.

For the full fiscal year, the Company forecasts higher revenues from expanded domestic sales of prescription drugs centered on Crestor, as well as increased royalty income from industrial property rights.

Although research and development expenses are expected to increase in tandem with the steady progress of products under development, Shionogi projects that operating income, ordinary income and net income will all increase as a result of sales growth and efforts to cut costs, including reducing raw material costs and lowering costs regularly borne in general and administrative expenses.

(2) Analysis of Financial Position

Assets, Liabilities and Net Assets

Total assets at September 30, 2007 were ¥420,361 million, a decrease of ¥9,208 million compared with the end of the previous fiscal year. The principal factors in the decrease were a decrease in cash and deposits due to payment of income tax and a decrease in investments in securities due to lower market values reflecting the downward trend of stock prices. As of September 30, 2007, certificates of deposit (domestic), formerly reported as cash and deposits, are reported as marketable securities. Total liabilities decreased ¥9,932 million from the previous fiscal year-end, mainly due to decreases in accrued income taxes and deferred tax liabilities. Net assets increased ¥723 million due to a decrease in unrealized gain on securities, an increase in retained earnings and other factors.

Cash Flow

Net cash provided by operating activities increased ¥7,003 million compared with the same period of the previous fiscal year to ¥9,178 million due to an increase in income, a decrease in income tax paid and other factors.

Net cash used in investment activities was ¥8,598 million, primarily for capital expenditures for manufacturing facilities and purchase of investment securities.

Net cash used in financing activities totaled ¥4,081 million, due to factors including cash dividends paid to shareholders of the Company and purchase of treasury stock.

As a result, cash and cash equivalents at September 30, 2007 stood at ¥71,131 million, a decrease of ¥3,414 million from March 31, 2007.

Trends in Cash Flow Indicators

	Year ended March 2006	Six months ended September 2006	Year ended March 2007	Six months ended September 2007
Net worth ratio (%)	78.8	79.8	80.4	82.4
Net worth ratio calculated based on market value (%)	153.8	173.8	168.0	143.2
Interest-bearing liabilities/ Cash flow ratio	0.2	0.7	0.2	0.1
Interest coverage ratio (times)	72.1	68.6	225.6	374.8

Notes:

tes: Net worth ratio: Net worth/Total assets

Net worth ratio calculated based on market value: Total market value of stock/Total assets

Interest-bearing liabilities/Cash flow ratio: Interest-bearing liabilities/Cash flow

(Net cash flows in the interim period represent double the amount of actual cash flows.)

Interest coverage ratio: Net cash provided by operating activities/Interest expense

- 1. All indicators are calculated on a consolidated basis.
- Total market value of stock is calculated based on the total number of shares outstanding excluding treasury stock.
- 3. Cash flow is net cash provided by operating activities as reported in the consolidated statement of cash flows.
- 4. Interest-bearing liabilities are liabilities stated on the consolidated balance sheets on which interest is paid.

(3) Fundamental Policy on Appropriation of Retained Earnings

In order to increase corporate value from a medium-to-long-term perspective, Shionogi aggressively invests in its business. Moreover, while Shionogi follows a policy of distributing dividends in proportion to results for each fiscal term, it aims to make stable increases. Internal capital reserves are mainly earmarked for capital demands for future business development, including investment in research and development of new products. Shionogi has set a target of raising its payout ratio to 35 percent by the fiscal year ending March 31, 2010.

For the fiscal year ending March 31, 2008, Shionogi will pay an interim dividend of ¥10 per share, and plans to pay a year-end dividend of ¥10 per share. As a result, total cash dividends for the fiscal year will be ¥20 per share, a year-on-year increase of ¥4 per share.

Furthermore, at its meeting on September 18, 2007, the Board of Directors resolved to repurchase a maximum of 5,500,000 shares of treasury stock at a cost of ¥10.0 billion during the period from September 19 to November 16 in order to raise the level of shareholder returns and improve capital efficiency.

(4) Business and Other Risks

Health Care System and Regulatory Risk

Trends in the ethical drug industry in Japan, including further revision of the National Health Insurance (NHI) system and its drug pricing system, may exert a material influence on the Shionogi Group's business results.

Risk of Pharmaceutical Side Effects

Possible events such as termination of production or recall of pharmaceutical products due to the occurrence of unforeseen side effects may exert a material influence on the Shionogi Group's business results.

Pharmaceutical Research and Development Risks

Research and development of ethical drugs requires a substantial investment of business resources and time. In addition, various uncertainties exist during the period leading up to the actual launch of a new drug. There also exist possible risks that our various intellectual property rights may fail to fully protect our products and/or infringe intellectual property rights.

Intensifying Global Competition

Competition in the ethical drug industry, including competition with foreign companies, is intensifying in the areas of research and development and sales.

Other Risks

The occurrence of natural disasters or calamities may exert a material influence on the Shionogi Group's business results. Other risks include, but are not limited to, governmental and financial factors.


Companies in the Shionogi Group

As of September 30, 2007, the Shionogi Group consisted of Shionogi & Co., Ltd. (the "Company"), 10 consolidated subsidiaries and 6 affiliates. These companies are engaged primarily in the manufacture and sale of ethical drugs. In addition, they render related services.

The business segments of the Company, and its subsidiaries and affiliates are summarized as follows:

Business segments	Main products/ merchandise and services	Major companies		
Pharmaceuticals and	Ethical drugs, OTC drugs and	Shionogi & Co., Ltd.		
related businesses	Diagnostics	Bushu Pharmaceuticals Ltd.		
	-	Nichia Pharmaceutical Industries Ltd.		
		Takata Seiyaku Co., Ltd.		
		Omwell Co., Ltd.		
		Taiwan Shionogi & Co., Ltd.		
		Shionogi USA, INC.		
		Shionogi-GlaxoSmithKline Holdings L.P.		
		4 other companies	(12 companies in total)	
Other businesses	Real estate leasing,	Shionogi General Service Co., Ltd.		
	Physical distribution and other	Shionogi Buturyuu Service Co., Ltd.		
	services	Shionogi Engineering Service Co., Ltd.		
		2 other companies	(5 companies in total)	

A business organizational chart illustrating the above-mentioned activities is presented on the next page.



Note: Three consolidated subsidiaries and 2 affiliates are not shown in this chart as the scale of their business is very small.

Management Policy

(1) Fundamental Management Policy

Shionogi's corporate philosophy is to "constantly strive to provide medicine of the best possible kind essential for protection of the health of the people." For this purpose, we must create and manufacture better and better pharmaceuticals, while ensuring that as many people as possible know about and use them. To accomplish this goal, we believe that having all of Shionogi's people improve technologies day by day enables us to contribute to expanding the benefits we offer to our customers, shareholders, business partners, society, our employees and all our other stakeholders.

(2) Management Strategy and Challenges Ahead

The operating environment of the pharmaceutical industry is expected to become increasingly severe due to further progress in the consideration of healthcare system reforms, together with rising research and development expenditures, intensifying international competition and other factors.

Under these conditions, the Shionogi Group will focus on steadily implementing its second medium-term management plan, which actively promotes measures for long-term development, with the prescription drug business at the core. In addition to strengthening efforts in sales and marketing, where Shionogi has revised its plan due to the market environment and strategic issues, Shionogi will focus on the following themes in particular during the three years to March 2010, the final year of the second medium-term management plan.

- In research and development, Shionogi will enhance its framework for continuously discovering and developing
 world-class drugs. In addition to working on compounds currently under development, the Company will focus on
 building an organizational framework and educating personnel for simultaneous development of internationally
 competitive drugs in Japan, the United States and the European Union. Shionogi will also concentrate on strategic
 alliances.
- In sales and marketing, Shionogi will work to expand market share by concentrating resources on Crestor, Finibax, Avelox and other new products, and will strengthen activities to relieve the pain and improve the quality of life of cancer patients. Taking market structure into account, Shionogi will enhance efforts at advanced treatment hospitals, and will also take steps to strengthen its sales organization. This will include creating positions for marketing plan promoters who have a detailed understanding of medical needs.
- In "preparing for a significant leap forward," Shionogi will strengthen drug discovery research for drug "seeds," aggressively in-license and enhance its organization for overseas business development. In addition, over the next three years the Company plans to make strategic investments totaling more than ¥60 billion in manufacturing, research, development and other areas.

"Shionogi strives constantly to provide medicine of the best possible kind essential for protection of the health of the people." By implementing the second medium-term business plan, the Company is working to realize this mission and further increase its presence as a pharmaceutical company.

Management indicator targets for the year ending March 2010 are as follows:

Net sales	270 billion yen
Operating income	80 billion yen
Net income	48 billion yen

Interim Consolidated Statements of Income

						(Units:	Millions of yen)
Period	Six months	ended	Six months	ended	Increase	Year ended Ma	arch 31 2007
	September	30, 2007	September 3	30, 2006	(Decrease)		aich 31, 2007
Account	Amount	Percentage	Amount	Percentage	Amount	Amount	Percentage
		%		%			%
Net sales	104,167	100.0	92,154	100.0	12,013	199,759	100.0
Cost of sales	34,685	33.3	30,609	33.2	4,076	67,542	33.8
Gross profit	69,482	66.7	61,544	66.8	7,938	132,216	66.2
Selling, general and administrative expenses	52,337	50.2	50,560	54.9	1,777	103,353	51.7
Operating income	17,145	16.5	10,984	11.9	6,161	28,863	14.5
Non-operating income	1,908	1.8	1,599	1.7	309	3,368	1.7
Interest income	670		477		193	1,141	
Dividends income	630		499		131	661	
Real estate rent	330		290		40	597	
Other	278		331		(53)	968	
Non-operating expenses	1,903	1.8	1,606	1.7	297	4,118	2.1
Interest expenses	43		47		(4)	95	
Contribution	532		474		58	1,272	
Loss on disposal of inventories	474		_		474	1,057	
Loss on disposal of fixed assets	531		282		249	558	
Other	320		801		(481)	1,134	
Ordinary income	17,150	16.5	10,977	11.9	6,173	28,113	14.1
Extraordinary income	276	0.2	509	0.6	(233)	3,610	1.8
Gain on sales of investment securities	276		120		156	186	
Gain on reversal of co-development cost of previous years	-		389		(389)	657	
Gain on exchange of investment securities	_		-		_	2,765	
Extraordinary loss	25	0.0	_	_	25	-	_
Loss on sales of stocks of affiliates	25		_		25	_	
Income before income taxes	17,401	16.7	11,487	12.5	5,914	31,723	15.9
Income taxes-current	3,737	3.6	1,552	1.7	2,185	8,702	4.4
Income taxes-deferred	2,868	2.7	3,517	3.9	(649)	4,387	2.2
Minority interests in income	(6)	(0.0)	(23)	(0.0)	17	(39)	(0.0)
Net income	10,788	10.4	6,394	6.9	4,394	18,594	9.3

Interim Consolidated Balance Sheets

(Units : Millions of yen)

Period	As of Septemb	er 30, 2007	As of March	n 31,2007	Increase (Decrease)	As of September 30, 2006	
Account	Amount	Percentage	Amount	Percentage	Amount	Amount	Percentage
(Assets)		%		%			%
Current Assets							
Cash and deposits	70,317		86,853		(16,536)	82,932	
Notes and accounts receivable-trade	64,259		67,575		(3,316)	64,113	
Marketable securities	17,335		_		17,335	_	
Inventories	35,541		32,395		3,146	31,418	
Deferred tax assets	3,911		5,325		(1,414)	4,542	
Other	13,595		16,753		(3,158)	19,056	
Allowance for doubtful accounts	(12)		(12)		0	(12)	
Total Current assets	204,948	48.8	208,890	48.6	(3,942)	202,051	47.5
Fixed exects							
Fixed assets							
Property, plant and equipment							
Buildings and structures	30,256		31,142		(886)	30,730	
Machinery, equipment and vehicles	10,528		10,837		(309)	11,180	
Land	14,812		14,812		0	14,811	
Construction in progress	8,126		5,172		2,954	3,952	
Other	5,715		5,850		(135)	5,402	
Property, plant and equipment, net	69,439	16.5	67,815	15.8	1,624	66,077	15.6
Intangible fixed assets	6,098	1.4	6,135	1.4	(37)	6,772	1.6
Investments and other assets							
Investment securities	115,580		123,368		(7,788)	129,040	
Prepaid pension cost	21,760		20,168		1,592	17,782	
Other	2,702		3,360		(658)	3,595	
Allowance for doubtful accounts	(168)		(168)		0	(165)	
Total investments and other assets	139,875	33.3	146,728	34.2	(6,853)	150,253	35.3
Total fixed assets	215,413	51.2	220,679	51.4	(5,266)	223,104	52.5
Total assets	420,361	100.0	429,569	100.0	(9,208)	425,155	100.0

Period As of September 30, 2007 As of March 31,2007 Increase (Decrease) As of September 30, 2006 Account Amount Percentage Amount Percentage Amount Percentage (Liabilities) S S S Amount Percentage Amount Percentage Notes and accounts payable-trade 12,602 12,189 413 14,427 S Accound income taxes 3,384 7,563 G(3,579) 1,696 S Reserves 1,030 1,088 G(3,879) 989 S Other reserves 1,030 1,088 G(2,977) 25,121 S Total current liabilities 21,711 24,698 (2,987) 25,121 S Deferred tax liabilities 21,711 24,698 (106) 8,486 S <th></th> <th></th> <th></th> <th>-</th> <th></th> <th></th> <th>Unit:</th> <th>s : Millions of yen)</th>				-			Unit:	s : Millions of yen)
Amount Percentage Amount Percentage Amount Amount Percentage (Liabilities) x		As of Septemb	er 30, 2007	As of March	1 31,2007		As of Septer	ber 30, 2006
Current liabilities I	Account	Amount	Percentage	Amount	Percentage	Amount	Amount	Percentage
Notes and accounts payable trade 12,002 12,189 413 14,427 Accrued income taxes 3,984 7,563 (3,579) 1,696 Reserves 1,000 10,886 (68,5) 9,894 Other reserves 1,000 20,735 (3,735) 22,4649 Total current liabilities 41,074 9.8 47,535 11.1 (6,61) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 14.4 Reserves 168 185 (106) 8,486 145 11.1 14,647 Deferred tax liabilities 21,711 24,698 (107) 185 11.4 Conserves 168 185 (106) 8,486 185 11.1 14,427 Other reserves 168 185 (107) 185 11.4 14,427 Cong-term accounts payable-other 9.96 9.78 18 9.59 20.22 Other 9.96 9.78 18 <	(Liabilities)		%		%			%
payable-trade 12.002 12.109 413 14.427 Accrued income taxes 3,984 7,563 (3,579) 1,696 Reserves 1,030 1,088 (58) 989 Other reserves 1,030 1,088 (58) 989 Other 17,000 20,735 (3,735) 24,649 Non-current liabilities 41,074 9.8 47,535 11.1 (6,461) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,967) 25,121 11.4 Non-current liabilities 21,711 24,698 (17) 185 11.4 Other reserves 168 185 (17) 185 11.4 18.496 11.4 Other 996 976 18 959 1041 959 1041 19.50 20.22 1041 19.50 20.22 1041 19.50 20.22 1041 13.837 17.6 83.817 19.5 0.90.227 4.7 Other	Current liabilities							
Reserves Reserves 6,455 5,958 497 6,827 Other reserves 1,030 1,088 (6,8) 989 Other 17,000 20,735 (3,735) 24,649 Total current liabilities 41,074 9.8 47,535 11.1 (6,61) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 11.1 14.661) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 11.1 14.661) 48,486 Other reserves 168 185 (17) 185 11.1 185 11.1 18.99 11.1 18.99 11.1 18.1 18.1 19.5		12,602		12,189		413	14,427	
Reserve for bonuses Other reserves 6,455 1,030 5,958 1,030 497 1,088 6,827 (58) 989 989 Other 17,000 20,735 (3,735) 24,649 Total current liabilities 41,074 9.8 47,535 11.1 (6,461) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 11.4 Deferred tax liabilities 21,711 24,698 (106) 8,486 11.4 Other reserves 168 185 (17) 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.4 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 185 11.1 11.1	Accrued income taxes	3,984		7,563		(3,579)	1,696	
Other reserves Other1,030 17,0001,088 20,735(58) (58)9.89 90 (3,735)Other17,00020,735(3,735)24,649Total current liabilities Deferred tax liabilities Beserves21,71124,698(2,987)25,121Reserves Reserves21,71124,698(2,987)25,121Reserves Deferred tax liabilities Deferred tax liabilities8,2468,352(106)8,486Other reserves168185(17)185Long-term accounts payable-other1,6892,066(377)2,451Other99697818959Total non-current liabilities32,8117.836,2818.4(3,470)37,2058.8Total non-current liabilities73,88517.683,81719.5(9,932)85,79620.2(Net assets) Owners' equity Capital surplus20,2274.820,2274.7020,2274.7Retained earnings Teasury stock21,2795.121,2795.0021,2795.0Capital surplus valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Total owners' equity316,37875.7311,2897.2.57.089301,90071.0Valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Total owners's Valuation and translation adjustments27,8096	Reserves							
Other 17,000 20,735 (3,735) 24,649 Total current liabilities 41,074 9.8 47,535 11.1 (6,461) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 10000 10000 10000 10000 10000 10000 10000 10000	Reserve for bonuses	6,455		5,958		497	6,827	
Total current liabilities 11,074 9.8 47,535 11.1 (6,461) 48,591 11.4 Non-current liabilities 21,711 24,698 (2,987) 25,121 11.4 Reserves 8,246 8,352 (106) 8,486 11.4 11.4 Other reserves 168 185 (17) 185 11.4 11.4 Long-term accounts payable-other 1,689 2.066 (377) 2.451 11.4 Other 996 978 18 959 11.4 11.4 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total non-current liabilities 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital suck 21,279 5.1 21,279 5.0 0 21,279 5.0 20,227 4.7	Other reserves	1,030		1,088		(58)	989	
Non-current liabilities 21,711 24,698 (2,987) 25,121 Reserves 8,246 8,352 (106) 8,486 Other reserves 168 185 (17) 185 Long-term accounts payable-other 1,689 2,066 (377) 2,451 Other reserves 1,689 2,066 (377) 2,451 Total non-current liabilities 32,811 7.8 36,221 8.4 (3,470) 37,205 8.8 Total non-current liabilities 32,811 7.8 36,221 8.4 (3,470) 37,205 8.8 Total non-current liabilities 32,811 7.8 36,221 8.4 (3,470) 37,205 8.8 Total non-current liabilities 32,811 7.8 32,211 9.90 20.2 (Net assets) 20,227 4.8 20,227 4.7 0 21,279 5.0 Capital suck 21,279 5.1 21,279 5.0 0 21,279 5.0 Treasury stock	Other	17,000		20,735		(3,735)	24,649	
Deferred tax liabilities Reserves 21,711 24,698 (2,987) 25,121 Reserves 8,246 8,352 (106) 8,486 Other reserves 168 185 (17) 185 Long-term accounts payable-other 996 978 18 959 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total non-current liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) Owners' equity 20,227 4.8 20,227 4.7 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Total owners' equity 318,378 75.7 311,289 72.5 7,089 301,980 71.0 Valuation and translation adjustment (1) (0.0) <td>Total current liabilities</td> <td>41,074</td> <td>9.8</td> <td>47,535</td> <td>11.1</td> <td>(6,461)</td> <td>48,591</td> <td>11.4</td>	Total current liabilities	41,074	9.8	47,535	11.1	(6,461)	48,591	11.4
Reserves Reserves for retirement benefits 8.246 8.352 (106) 8.486 Other reserves 168 185 (17) 185 Long-term accounts payable-other 1.689 2.066 (377) 2.451 Other 996 978 18 959 Total non-current liabilities 32.811 7.8 36.281 8.4 (3.470) 37.205 8.8 Total non-current liabilities 73.885 17.6 83.817 19.5 (9.932) 85.796 20.2 (Net assets) Owners' equity Capital surplus 20.227 4.8 20.227 4.7 0 20.227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8.065 269,394 63.4 Treasury stock (10.064) (2.4) (9.088) (2.1) (976) (8.920) (2.1) Total owners' equity 318,378 75.7 311,289 72.5 7.089 301,980 71.0 Valuation and translation adjustments	Non-current liabilities							
Reserve for retirement benefits 8,246 8,352 (106) 8,486 Other reserves 168 185 (17) 185 Long-term accounts payable-other 1,689 2,066 (377) 2,451 Other 996 978 8 959 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 21,279 5.1 21,279 5.0 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,934 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Valuation and translation adjustments 27,810 6.6 34,262	Deferred tax liabilities	21,711		24,698		(2,987)	25,121	
benefits 8,246 8,352 (106) 8,486 Other reserves 168 185 (17) 185 Long-term accounts payable-other 1,689 2,066 (377) 2,451 Other 996 978 18 959 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total non-current liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital surplus 20,227 4.8 20,227 4.7 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Valuation adfurshent 27,810 6.6 34,262 7.9 (6,4	Reserves							
Long-term accounts payable-other 1,689 2,066 (377) 2,451 Other 996 978 18 959 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) Owners' equity 20,227 4.8 20,227 4.7 0 20,227 4.7 Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 21,279 5.1 21,279 5.0 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Valuation and translation adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8		8,246		8,352		(106)	8,486	
payable-other Other 1,069 2,000 (377) 2,451 Other 996 978 18 959 Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) Owners' equity 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 21,279 5.1 21,279 5.0 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Total owners' equity 318,378 75.7 311,289 72.5 7,089 301,980 71.0 Valuation and translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1)	Other reserves	168		185		(17)	185	
Total non-current liabilities 32,811 7.8 36,281 8.4 (3,470) 37,205 8.8 Total liabilities 73,885 17.6 83,817 19.5 (9,932) 85,796 20.2 (Net assets) 0wners' equity 5.1 21,279 5.0 0 21,279 5.0 Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 20,227 4.8 20,227 4.7 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Valuation and translation adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustment 27,809		1,689		2,066		(377)	2,451	
Total liabilities The	Other	996		978		18	959	
(Net assets) 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 20,227 4.8 20,227 4.7 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Total owners' equity 318,378 75.7 311,289 72.5 7,089 301,980 71.0 Valuation and translation adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustment 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1	Total non-current liabilities	32,811	7.8	36,281	8.4	(3,470)	37,205	8.8
Owners' equity Image: Capital stock 21,279 5.1 21,279 5.0 0 21,279 5.0 Capital stock 20,227 4.8 20,227 4.7 0 20,227 4.7 Retained earnings 286,936 68.2 278,871 64.9 8,065 269,394 63.4 Treasury stock (10,064) (2.4) (9,088) (2.1) (976) (8,920) (2.1) Total owners' equity 318,378 75.7 311,289 72.5 7,089 301,980 71.0 Valuation and translation adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustment 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Total valuation and translation adjustments 287 0.1 283 0.1 4 268 0.1 Minori	Total liabilities	73,885	17.6	83,817	19.5	(9,932)	85,796	20.2
Capital stock21,2795.121,2795.0021,2795.0Capital surplus20,2274.820,2274.7020,2274.7Retained earnings286,93668.2278,87164.98,065269,39463.4Treasury stock(10,064)(2.4)(9,088)(2.1)(976)(8,920)(2.1)Total owners' equity318,37875.7311,28972.57,089301,98071.0Valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Translation adjustment(1)(0.0)(83)(0.0)82(189)(0.1)Total valuation and translation adjustments27,8096.634,1787.9(6,369)37,1098.7Minority interests2870.12830.142680.1Total net assets346,47582.4345,75280.5723339,35879.8	(Net assets)							
Capital surplus20,2274.820,2274.7020,2274.7Retained earnings286,93668.2278,87164.98,065269,39463.4Treasury stock(10,064)(2.4)(9,088)(2.1)(976)(8,920)(2.1)Total owners' equity318,37875.7311,28972.57,089301,98071.0Valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Translation adjustment(1)(0.0)(83)(0.0)82(189)(0.1)Total valuation and translation adjustments27,8096.634,1787.9(6,369)37,1098.7Total valuation and translation adjustments27,8096.634,1787.9(6,369)37,1098.7Total net assets346,47582.4345,75280.5723339,35879.8	Owners' equity							
Retained earnings286,93668.2278,87164.98,065269,39463.4Treasury stock(10,064)(2.4)(9,088)(2.1)(976)(8,920)(2.1)Total owners' equity318,37875.7311,28972.57,089301,98071.0Valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Translation adjustment(1)(0.0)(83)(0.0)82(189)(0.1)Total valuation and translation adjustments27,8096.634,1787.9(6,369)37,1098.7Minority interests2870.12830.142680.1Total net assets346,47582.4345,75280.5723339,35879.8		21,279	5.1	21,279	5.0	0	21,279	5.0
Treasury stock(10,064)(2.4)(9,088)(2.1)(976)(8,920)(2.1)Total owners' equity318,37875.7311,28972.57,089301,98071.0Valuation and translation adjustments27,8106.634,2627.9(6,452)37,2988.8Translation adjustment(1)(0.0)(83)(0.0)82(189)(0.1)Total valuation and translation adjustments27,8096.634,1787.9(6,369)37,1098.7Minority interests2870.12830.142680.1Total net assets346,47582.4345,75280.5723339,35879.8	Capital surplus	20,227	4.8	20,227	4.7	0	20,227	4.7
Total owners' equity 318,378 75.7 311,289 72.5 7,089 301,980 71.0 Valuation and translation adjustments Valuation difference on available-for-sale securities 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8	Retained earnings	286,936	68.2	278,871	64.9	8,065	269,394	63.4
Valuation and translation adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Valuation difference on available-for-sale securities (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8	Treasury stock	(10,064)	(2.4)	(9,088)	(2.1)	(976)	(8,920)	(2.1)
adjustments 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Valuation difference on available-for-sale securities (1) (0.0) (83) (0.0) 82 (189) (0.1) Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8	Total owners' equity	318,378	75.7	311,289	72.5	7,089	301,980	71.0
available-for-sale securities 27,810 6.6 34,262 7.9 (6,452) 37,298 8.8 Translation adjustment (1) (0.0) (83) (0.0) 82 (189) (0.1) Total valuation and translation adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8								
Total valuation and translation adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8		27,810	6.6	34,262	7.9	(6,452)	37,298	8.8
adjustments 27,809 6.6 34,178 7.9 (6,369) 37,109 8.7 Minority interests 287 0.1 283 0.1 4 268 0.1 Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8	-	(1)	(0.0)	(83)	(0.0)	82	(189)	(0.1)
Total net assets 346,475 82.4 345,752 80.5 723 339,358 79.8		27,809	6.6	34,178	7.9	(6,369)	37,109	8.7
	Minority interests	287	0.1	283	0.1	4	268	0.1
Total liabilities and net assets 420,361 100.0 429,569 100.0 (9,208) 425,155 100.0	Total net assets	346,475	82.4	345,752	80.5	723	339,358	79.8
	Total liabilities and net assets	420,361	100.0	429,569	100.0	(9,208)	425,155	100.0

Interim Consolidated Statements of Changes in Net Assets

[Six months ended September 30, 2007]

			Owners' equity		
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total owners equity
Balance at March 31, 2007	21,279	20,227	278,871	(9,088)	311,289
Changes of items during the period					
Dividends from surplus			(2,723)		(2,723)
Net income			10,788		10,788
Purchase of treasury stock				(975)	(975)
Net changes of items other than owners' equity					_
Total changes of items during the period	-	-	8,065	(975)	7,089
Balance at September 30, 2007	21,279	20,227	286,936	(10,064)	318,378

	Valuation	and translation adj	ustments			
	Valuation difference on available-for-sale securities	Translation adjustment	Total valuation and translation adjustments	Minority interests	Total net assets	
Balance at March 31, 2007	34,262	(83)	34,178	283	345,752	
Changes of items during the period						
Dividends from surplus					(2,723)	
Net income					10,788	
Purchase of treasury stock					(975)	
Net changes of items other than owners' equity	(6,452)	82	(6,369)	4	(6,365)	
Total changes of items during the period	(6,452)	82	(6,369)	4	723	
Balance at September 30, 2007	27,810	(1)	27,809	287	346,475	

[Six months ended September 30, 2006]

	- 1				(Units: Millions of ye		
	Owners' equity						
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total owners' equity		
Balance at March 31, 2006	21,279	20,227	266,469	(8,750)	299,226		
Changes of items during the period							
Dividends from surplus *			(3,406)		(3,406)		
Directors' bonuses *			(63)		(63)		
Net income			6,394		6,394		
Purchase of treasury stock				(170)	(170)		
Net changes of items other than owners' equity					_		
Total changes of items during the period	_	_	2,925	(170)	2,754		
Balance at September 30, 2006	21,279	20,227	269,394	(8,920)	301,980		

	Valuation	and translation adj	ustments		
	Valuation difference on available-for-sale securities	Translation adjustment	Total valuation and translation adjustments	Minority interests	Total net assets
Balance at March 31, 2006	38,116	(156)	37,959	247	337,433
Changes of items during the period					
Dividends from surplus *					(3,406)
Directors' bonuses *					(63)
Net income					6,394
Purchase of treasury stock					(170)
Net changes of items other than owners' equity	(817)	(33)	(850)	20	(829)
Total changes of items during the period	(817)	(33)	(850)	20	1,925
Balance at September 30, 2006	37,298	(189)	37,109	268	339,358

* Item for appropriation of unappropriated retained earnings at the Annual General Meeting of Shareholders held in June 2006.

[Year ended March 31,2007]

(Units: Millions of yen)

	Owners' equity						
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total owners' equity		
Balance at March 31,2006	21,279	20,227	266,469	(8,750)	299,226		
Changes of items during the period							
Dividends from surplus *			(3,406)		(3,406)		
Dividends from surplus			(2,724)		(2,724)		
Directors' bonuses *			(63)		(63)		
Net income			18,594		18,594		
Purchase of treasury stock				(337)	(337)		
Net changes of items other than owners' equity					_		
Total changes of items during the period	_	-	12,401	(337)	12,063		
Balance at March 31,2007	21,279	20,227	278,871	(9,088)	311,289		

	Valuation	and translation adj			
	Valuation difference on available-for-sale securities	Translation adjustment	Total valuation and translation adjustments	Minority interests	Total net assets
Balance at March 31,2006	38,116	(156)	37,959	247	337,433
Changes of items during the period					
Dividends from surplus *					(3,406)
Dividends from surplus					(2,724)
Directors' bonuses *					(63)
Net income					18,594
Purchase of treasury stock					(337)
Net changes of items other than owners' equity	(3,853)	72	(3,780)	35	(3,745)
Total changes of items during the period	(3,853)	72	(3,780)	35	8,318
Balance at March 31,2007	34,262	(83)	34,178	283	345,752

* Item for appropriation of unappropriated retained earnings at the Annual General Meeting of Shareholders held in June 2006.

Interim Consolidated Statements of Cash Flows

				(Units: Millions of yen)
		Six months ended	Six months ended	Year ended March
		September 30, 2007	September 30, 2006	31,2007
		Amount	Amount	Amount
Ι	Net cash provided by operating activities			
	Income before income taxes	17,401	11,487	31,723
	Depreciation and amortization	4,711	4,156	8,797
	Loss on disposal of property, plant and equipment	528	283	556
	Gain on sales of investment securities	(276)	(120)	(186)
	Gain on exchange of investment securities	—	—	(2,765)
	Decrease (increase) in allowance for doubtful accounts	(0)	2	5
	Decrease in reserve for retirement benefits	(1,698)	(2,254)	(4,773)
	Interest and dividends income	(1,300)	(977)	(1,802)
	Interest expenses	43	47	95
	Foreign exchange (gain) loss	(97)	0	(45)
	Decrease in notes and accounts receivable-trade	3,324	5,782	2,330
	Increase in inventories	(3,126)	(4,249)	(5,198)
	Increase in notes and accounts payable-trade	398	4,217	1,956
	Decrease (increase) in accrued expenses	(680)	635	585
	Decrease in accounts payable-other	(5,599)	(5,141)	(2,890)
	Other	1,229	(865)	(2,760)
	Subtotal	14,857	13,002	25,629
	Interest and dividends income received	1,473	1,154	1,971
	Interest expenses paid	(24)	(31)	(62)
	Income tax paid	(7,128)	(11,950)	(13,423)
	Net cash provided by operating activities	9,178	2,175	14,115
Π	Net cash used in investment activities			
	Payments into time deposits	(2,486)	(29,397)	(31,407)
	Proceeds from withdrawal of time deposits	2,368	14,335	33,649
	Purchase of marketable securities	(19)	(19)	(19)
	Proceeds from sales and redemption of marketable securities	2,024	2,020	4,020
	Purchase of investment securities	(5,204)	(2,308)	(4,316)
	Proceeds from sales of investment securities	282	375	861
	Purchases of property, plant and equipment	(4,779)	(4,160)	(11,410)
	Proceeds from sales of property, plant and equipment	7	12	28
	Collection of loans receivable	312	3	3
	Purchase of stock of affiliates	(634)	(1,099)	(1,693)
	Proceeds from sales of stock of affiliates	443	129	129
	Proceeds from exchange of investment securities	—	—	3,158
	Other	(914)	(847)	(1,420)
	Net cash used in investment activities	(8,598)	(20,957)	(8,418)
Ш	Net cash used in financing activities			
	Repayments of installment payables	(381)	(342)	(718)
	Purchase of treasury stock	(976)	(170)	(337)
	Cash dividends paid	(2,720)	(3,400)	(6,122)
	Cash dividends paid to minority shareholders	(2)	(2)	(2)
	Net cash used in financing activities	(4,081)	(3,916)	(7,180)
IV	Effect of exchange rate change on cash and cash equivalents	87	(53)	(113)
v	Decrease in cash and cash equivalents	(3,414)	(22,751)	(1,596)
	Cash and cash equivalents at beginning of period	74,546	76,142	76,142
	Cash and cash equivalents at end of period	71,131	53,390	74,546

Notes to Interim Consolidated Financial Statements

1. Scope of consolidation

Number of consolidated subsidiaries: 10 Bushu Pharmaceuticals Ltd., Nichia Pharmaceutical Industries Ltd., Saishin Igaku Co., Ltd., Shionogi Engineering Service Co., Ltd., Shionogi Butsuryuu Service Co., Ltd., Shionogi General Service Co., Ltd., Aburahi AgroResearch Co., Ltd., Taiwan Shionogi & Co., Ltd., Shionogi USA, Inc., SG Holding Inc.

2. Application of equity method

Shionogi-GlaxoSmithKline Holdings L.P. was accounted for by the equity method and its interim closing date differs from the interim consolidated closing date, therefore the interim financial statements in its fiscal year have been used. That portion of the net profit (loss) of the 5 affiliates not accounted for by the equity method which was attributable to the Company in

proportion to its shareholding ratio had no significant effect on the interim consolidated net income or retained earnings of the Company for the current period.

3. Closing date of consolidated subsidiaries

Three overseas consolidated subsidiaries close their accounts on June 30, for financial reporting purpose. The accompanying interim consolidated financial statements of the Company have been prepared on the basis of the consolidated subsidiaries' interim financial statements prepared as of their respective closing dates. The necessary adjustments have been made to reflect any significant transactions occurring between the respective closing dates and the date of the interim consolidated financial statements.

4. Significant accounting policies

(1) Basis and method of valuation of significant assets

1. Securities

A) Held-to-maturity securities

Amortized cost method

B) Other securities

a) Market value available

At fair value, based on market price or other appropriate quotation as of period end

(Unrealized gain is charged directly to net assets; cost of sales is accounted for by the moving average method.) b) Market value not available

At cost determined by the moving average method

(The securities based on Financial Products Exchange Law article 2.2 are evaluated their net profit/loss(equity method).)

2. Inventories

Most items are evaluated at cost determined by the average method.

(2) Depreciation method of significant depreciable assets

1. Property, plant and equipment

Most items are depreciated by the declining balance method.

Buildings (except for structures attached to the buildings) acquired subsequent to April 1, 1998 are depreciated by straight-line method.

The useful lives are as follows:

Buildings and structures:	2 to 60 years
Machinery and equipment and vehicles:	2 to 17 years

[Change of accounting policy]

In accordance with revisions to the Corporation Tax Law, for depreciation of tangible fixed assets acquired from April 1, 2007, the Company and its domestic consolidated subsidiaries have changed to a calculation method based on the revised Corporation Tax Law.

As a result, in the six months ended September 30, 2007, operating income, ordinary income and income before income taxes each decreased by ¥94 million compared with the former method.

The impact of this change on segment information is disclosed in 'Segment information'.

[Additional information]

In accordance with revisions to the Corporation Tax Law, the Company and its domestic consolidated subsidiaries depreciate tangible assets acquired before April 1, 2007 until the remaining value of assets reaches 5 percent of acquisition cost, as per pre-revision rules. Thereafter, the difference between the equivalent of 5 percent of the acquisition cost and the disposal cost is depreciated uniformly over five years as part of depreciation expenses.

As a result, in the six months ended September 30, 2007, operating income, ordinary income and income before income taxes each decreased by ¥441 million compared with the former method.

The impact of this change on segment information is disclosed in 'Segment information'.

2. Intangible fixed assets

Most items are depreciated by the Straight-line method

Expenditures related to computer software intended for internal use are amortized over the useful life of the respective assets (in general, 5 years).

(3) Basis for providing significant allowances and reserves

1. Allowance for doubtful accounts

The allowance for doubtful accounts is provided to cover bad debt loss. The amount provided for general receivables is based on the historical rate of bad debts; for certain receivable accounts of considerable risk, the estimated uncollectible amount is provided as an additional allowance after examining specific possibility of collection.

2. Reserve for bonuses

To prepare for payment of bonuses to employees, a reserve for bonuses is provided based on the estimated amount of bonuses to be paid.

3. Reserve for retirement benefits

To prepare for the payment of retirement benefits to employees, a reserve for retirement benefits is provided based on the retirement benefit liabilities accrued and the expected value of the pension plan assets as of the period end.

Prior service cost is amortized by the straight-line method over 10 years, which is within the estimated average remaining years of service of the eligible employees.

Actuarial gain or loss is proportionally amortized in the each year following the year in which the gain or loss is recognized principally by the straight-line method over 10 years, which is within the estimated average remaining years of service of the eligible employees.

(4) Foreign currency translation

Monetary receivables and payables denominated in foreign currencies are translated into Japanese yen at the interim balance sheet date. Gain or loss on translation is credited or charged to income; however, assets, liabilities, income and expenses of certain overseas consolidated subsidiaries are translated into Japanese yen at the rates of exchange in effect at the interim balance sheet date. Adjustments resulting from the translation of foreign currency interim financial statements have been reported as Translation adjustment in Net assets.

(5) Accounting for significant lease transactions

Finance leases other than those under which the leased property is deemed transferred to the lessee are accounted for as operating leases; however, certain overseas consolidated subsidiaries account for such finance leases as ordinary sales transactions.

(6) Significant hedge accounting

1. Method of hedge accounting

Gain (loss) resulting from forward foreign exchange contracts relating to transactions denominated in a foreign currency is allocated over the applicable periods.

2. Hedging instruments and hedged items

A) Hedging instruments

Forward foreign exchange contracts

B) Hedged items

Receivables and payables denominated in foreign currencies

3. Hedging policy

The Company enters into forward foreign exchange contracts to hedge against the risk of exchange rate fluctuation for receivables and payables denominated in foreign currencies.

(7) Other significant accounting policies

Consumption tax

Amounts reflected in the interim consolidated financial statements are stated exclusive of consumption tax.

[Change in method of presentation]

In accordance with amendments to the Guidelines to Regulations Governing Interim Consolidated Financial Statements specifying that certificates of deposit (domestic) are to be included in securities, from the six months ended September 30, 2007, certificates of deposit (domestic) included in cash and deposits prior to April 1, 2007 are reported as marketable securities. Certificates of deposit (domestic) included in marketable securities as of September 30, 2007 totaled ¥13,300 million. Certificates of deposit (domestic) included in cash and deposits as of September 30, 2006 totaled ¥2,300 million.

5. Definition of cash and cash equivalents in the interim consolidated cash flow statements

Cash and cash equivalents reported in the interim consolidated cash flow statements include cash on hand, bank deposits and deposits in other financial institutions immediately withdrawal upon request, or liquid short-term investments with only a minor risk of any fluctuation in their value which mature within three months of their acquisition dates.

Notes to interim consolidated financial statement

1. Notes to interim consolidated statements of income

	[Six months e	nded	[Six mor	nths ended		
	September	30, 2007]	Septer	nber 30, 2006]	[Year ended Ma	rch 31, 2007]
(1) The major items and amounts i	ncluded in selling,	general and adr	ministrative exper	nses were as follo	WS:	
Sales promotional activities	6,714	Million yen	5,706	Million yen	13,027	Million yen
Salaries	8,094		8,312		19,961	
Provision for reserve						
for bonuses	3,374		3,645		3,136	
Retirement benefit expenses	28		137		276	
R & D expenses	19,586	Million yen	17,874	Million yen	37,455	Million yen
(R&D expenses above include t Provision for reserve	he following amou	ints provided as	reserves and retin	rement benefit exp	penses)	
for bonuses	1,787	Million yen	1,863	Million yen	1,574	Million yen
Retirement benefit expenses	23		76		148	
2. Notes to interim consol	idated balan	ce sheets				
	[As of September	30, 2007]	[As of Mar	ch 31, 2007]	[As of Septem	ber 30, 2006]
 Accumulated depreciation of property, plant and equipment 	162,304	Million yen	161,459	Million yen	159,503	Million yen
(2) Guaranteed liabilities	80	Million yen	93	Million yen	102	Million yen
(3) Commitments - Lines of credit The Company entered into line- The outstanding balances of the			ncial institutions i	n order to enhanc	e its working capital e	fficiency.
Total amount of lines of credit The amount of borrowing	24,000	Million yen	24,000	Million yen	24,000	Million yen
Outstanding balances	24,000	Million yen	24,000	Million yen	24,000	Million yen
(4) Pledged assets and secured lia The assets listed below have be Book value of pledged assets:		llateral against b	porrowings and ot	her debts:		
Cash and deposits Liabilities secured by the above		Million yen	5	Million yen	5	Million yen
'Other' of current liabilities	6	Million yen	6	Million yen	6	Million yen
(5) Accounting for settlement of no In general, the settlement of no 2007 each fell on a bank holida which matured but were not set	tes is recorded on y, the balances of	the clearing dat notes receivable				

 Notes payable
 5
 Million yen
 7
 Million yen
 9
 Million yen

 (Including notes payable related to construction and installation contracts)
 7
 Million yen
 9
 Million yen

3. Notes to interim consolidated statement of changes in net assets

[Six months ended September 30, 2007]

- (1) 1	Type and number of shares	(Units: Shares)			
		March 31, 2007	Increase	Decrease	September 30, 2007
	Shares in issue				
	Common stock	351,136,165	—	-	351,136,165
	Total	351,136,165	-	-	351,136,165
	Treasury stock				
	Common stock	10,683,759	550,056	-	11,233,815
	Total	10,683,759	550,056	_	11,233,815

Note: The increase of 550,056 shares of treasury stock in common stock consists of a purchase of 50,056 odd-lot shares and a purchase of 500,000 shares approved by a resolution of the Board of Directors.

(2) Matters concerning subscription rights and subscription rights owned by the Company $N\!/\!A$

(3) Dividends

A) Dividend payments

Resolution	Category	Total amount of dividends	Amount per share	Dividend record date	Effective date
Annual General Meeting of Shareholders held on June 28, 2007	Common stock	2,723 Million yen	8 Yen	March 31, 2007	June 29, 2007

B) Dividends whose effective date is subsequent to September 30, 2007

Resolution	Category	Total amount of dividends	Funds for dividend	Amount per share	Dividend record date	Effective date
Board of Directors Meeting held on November 5, 2007	Common stock	3,399 Million yen	Retained earnings	10 Yen	September 30, 2007	December 3, 2007

[Six months ended September 30, 2006]

(1)]	Type and number of shares	(Units: Shares)			
		March 31, 2006	Increase	Decrease	September 30, 2006
	Shares in issue				
	Common stock	351,136,165	_	_	351,136,165
	Total	351,136,165	-	_	351,136,165
	Treasury stock				
	Common stock	10,526,605	83,182	-	10,609,787
	Total	10,526,605	83,182	-	10,609,787

Note: The increase in treasury stock reflects the purchase of odd-lot shares.

(2) Matters concerning subscription rights and subscription rights owned by the Company $N\!/\!A$

(3) Dividends

A) Dividend payments

Resolution	Category	Total amount of dividends	Amount per share	Dividend record date	Effective date
Annual General Meeting of Shareholders held on June 29, 2006	Common stock	3,406 Million yen	10 Yen	March 31, 2006	June 30, 2006

B) Dividends whose effective date is subsequent to September 30, 2006

Resolution	Category	Total amount of dividends	Funds for dividend	Amount per share	Dividend record date	Effective date
Board of Directors Meeting held on November 6, 2006	Common stock	2,724 Million yen	Retained earnings	8 Yen	September 30, 2006	December 1, 2006

[Year ended March 31, 2007]

(1)	Type and number of shares	in issue and type and num	ber of shares of treasury	stock	(Units: Shares)
		Decrease	March 31, 2007		
	Shares in issue				
	Common stock	351,136,165	_	-	351,136,165
	Total	351,136,165	_	_	351,136,165
	Treasury stock				
	Common stock	10,526,605	157,154	-	10,683,759
	Total	10,526,605	157,154	Ι	10,683,759

Note: The increase in treasury stock reflects the purchase of odd-lot shares.

(2) Matters concerning subscription rights and subscription rights owned by the Company $N\!/\!A$

(3) Dividends

A) Dividend payments

Resolution	Category	Total amount of dividends	Amount per share	Dividend record date	Effective date
Annual General Meeting of Shareholders held on June 29, 2006	Common stock	3,406 Million yen	10 Yen	March 31, 2006	June 30, 2006
Meeting of Board of directors on November 6, 2006	Common stock	2,724 Million yen	8 Yen	September 30, 2006	December 1, 2006

B) Dividends whose effective date is subsequent to March 31, 2007

Resolution	Category	Total amount of dividends	Funds for dividend	Amount per share	Dividend record date	Effective date
Annual General Meeting of Shareholders to be held on June 28, 2007	Common stock	2,723 Million yen	Retained earnings	8 Yen	March 31, 2007	June 29, 2007

4. Notes to interim consolidated statements of cash flow

Reconciliation of balance of cash and cash equivalents as of the period end with the amounts reported in the interim consolidated balance sheets:

	[As of September 30, 2007]	[As of September 30, 2006]	[As of March 31, 2007]
Cash and deposits	70,317 Million yen	82,932 Million yen	86,853 Million yen
Time deposits with a maturity exceeding three months	(12,486)	(29,542)	(12,307)
Cash and cash equivalents Including "Marketable securiting Cash and cash equivalents	es" <u>13,300</u> 71,131 Million yen	53,390 Million yen	 74,546 Million yen

5. Notes to lease transactions

Finance leases other than those under which the leased property is deemed transferred to the lessee:

[Six	months	ended	[Six mor	nths ended		
S	eptembe	r 30, 2007]	Septer	ber 30, 2006]	[Year ended Ma	arch 31, 2007]
(1) Acquisition cost equivalent, accumulate	d deprec	iation equivalent a	and period end b	alance equivalent	of leased properties	
Acquisition cost equivalent	2,057	Million yen	1,995	Million yen	1,985	Million yen
Accumulated depreciation equivalent	973		738		531	
Period-end balance	1,084	Million yen	1,257	Million yen	1,453	Million yen
Note: Tool and furniture account for mo	st of the	above balances.				
(2) Breakdown of period end balance equiv	alent of	unexpired leases				
Within one year	463	Million yen	455	Million yen	448	Million yen
Exceeding one year	620		801		1,005	
Total	1,084	Million yen	1,257	Million yen	1,453	Million yen
(3) Lease payments and depreciation equiv	valent					
Lease payments	309	Million yen	455	Million yen	296	Million yen
Depreciation equivalent	309	Million yen	455	Million yen	296	Million yen

(4) Calculation of depreciation equivalent

The lease period is deemed as the useful life of the leased property. The acquisition cost equivalent is depreciated by the straight-line method over the useful life, assuming a nil residual value.

Note: The amounts shown in 1 and 2 above include the interest portion.

[Impairment loss]

Impairment loss has not been allocated to leased assets.

6. Notes to securities

(1) Bonds to be held until maturity with quoted market prices

(י)	Bolida to be field di			tot phoes					(Units: N	lillions of yen)	
		As of S	September 30	, 2007	As o	of March 31, 2	007	As of	As of September 30, 2006		
		Value reported in interim consolidated balance sheet	Market price	Difference	Value reported in annual consolidated balance sheet	Market price	Difference	Value reported in interim consolidated balance sheet	Market price	Difference	
(1)	National, local government and other public bonds Corporate bonds	40,097	40,158	60	40,117	40,086	(30)	40,141	40,063	(77)	
(3)	Other bonds	19	19	0	19	19	0	19	19	0	
	Total	40,117	40,178	60	40,137	40,106	(30)	40,161	40,083	(77)	

(2) Other securities; market value available

(-)									(Units: N	lillions of yen)	
		As of	September 30	, 2007	As	As of March 31, 2007			As of September 30, 2006		
		Acquisition cost	Value reported in interim consolidated balance sheet	Difference	Acquisition cost	Value reported in annual consolidated balance sheet	Difference	Acquisition cost	Value reported in interim consolidated balance sheet	Difference	
(1)	Stocks	20,240	66,234	45,993	17,054	73,700	56,645	15,748	77,505	61,756	
(2)	Bonds										
	[1] National, local government and other public bonds	_	_	_	_	_	_	_	_	_	
	[2] Corporate bonds	_	-	_	-	-	_	_	-	_	
	[3] Other bonds	1,791	2,596	805	1,810	2,726	915	1,829	2,749	920	
(3)	Other securities	5,000	5,020	20	5,005	5,125	120	5,005	5,121	115	
	Total	27,032	73,851	46,819	23,870	81,551	57,681	22,583	85,375	62,792	

(3) Major securities (market value not available) and their value reported in interim consolidated balance sheets

(-)	·)· ··· (·			(Units: Millions of yen)
		As of September 30, 2007	As of March 31, 2007	As of September 30, 2006
		Value reported in interim consolidated balance sheet	Value reported in annual consolidated balance sheet	Value reported in interim consolidated balance sheet
(1)	Bonds to be held until maturity	_	_	_
(2)	Other securities			
	[1] Unlisted stocks (excluding OTC stocks)	2,149	2,567	4,504
	[2] Certificates of deposits (domestic)	13,300	14,300	2,300

Note: Certificates of deposits (domestic) have been included in Marketable securities in the interim consolidated balance sheets as of September 30, 2007.

Certificates of deposits (domestic) have been included in Cash and deposits in the interim (annual) consolidated balance sheets as of March 31, 2007 and September 30, 2006.

7. Notes to derivative transactions

Market prices of derivative transactions

The Company did not have any open derivatives positions other than certain hedges against receivables and payables denominated in foreign currency as of September 30, 2007, March 31, 2007 and September 30, 2006.

8. Notes to segment information

1. Business segment information

[Six months ended September 30	[Six months ended September 30, 2007] (Units: millions of yen)								
Segment	Pharmaceuticals and related businesses	Other businesses	Total	Eliminations	Consolidated				
I . Net sales and operating income:									
Net sales									
(1) Sales to third parties	99,892	4,275	104,167	_	104,167				
(2) Inter-group sales and transfers	-	1,767	1,767	(1,767)	-				
Total	99,892	6,042	105,935	(1,767)	104,167				
Operating expenses	83,652	5,137	88,790	(1,767)	87,022				
Operating income	16,240	904	17,145	0	17,145				

[Six months ended September 30, 2006]

[Six months ended September 30	Six months ended September 30, 2006] (Units: millions of yen)							
Segment	Pharmaceuticals and related businesses	Other businesses	Total	Eliminations	Consolidated			
I . Net sales and operating income: Net sales								
(1) Sales to third parties	90,875	1,279	92,154	_	92,154			
(2) Inter-group sales and transfers	-	2,591	2,591	(2,591)	-			
Total	90,875	3,870	94,746	(2,591)	92,154			
Operating expenses	80,588	3,172	83,761	(2,591)	81,169			
Operating income	10,287	697	10,984	0	10,984			

[Year ended March 31, 2007]

(Units: millions of yen)

/i i ·i

Segment	Pharmaceuticals and related businesses	Other businesses	Total	Eliminations	Consolidated
I . Net sales and operating income:					
Net sales					
(1) Sales to third parties	191,914	7,844	199,759	_	199,759
(2) Inter-group sales and transfers	-	4,883	4,883	(4,883)	_
Total	191,914	12,728	204,642	(4,883)	199,759
Operating expenses	164,757	11,022	175,779	(4,883)	170,895
Operating income	27,157	1,706	28,863	0	28,863

Notes: 1 .Businesses of the Shionogi & Co., Ltd and consolidated subsidiaries are segmented into "Pharmaceuticals and related businesses" and "Other businesses", considering the types of products/merchandise handled and the similarities in their markets.

Major products/merchandise and services provided by each segment

Business segment	Major products/merchandise and services
Pharmaceuticals and related businesses	Ethical drugs, OTC drugs and Diagnostics
Other businesses	Real estate leases, Physical distribution and other services

3. Change of accounting policy

In accordance with revisions to the Corporation Tax Law, for depreciation of tangible fixed assets acquired from April 1, 2007, the Company and its domestic consolidated subsidiaries have changed to a calculation method based on the revised Corporation Tax Law.

With this change, operating expenses in the Pharmaceuticals and Related Businesses and the Other Businesses segments for the six months ended September 30, 2007 increased by ¥94 million and ¥0 million, respectively, compared with the former method, decreasing operating income in each segment by the same respective amount.

4. Additional information

In accordance with revisions to the Corporation Tax Law, the Company and its domestic consolidated subsidiaries depreciate tangible assets acquired before April 1, 2007 until the remaining value of assets reaches 5 percent of acquisition cost, as per pre-revision rules. Thereafter, the difference between the equivalent of 5 percent of the acquisition cost and the disposal cost is depreciated uniformly over five years as part of depreciation expenses. With this change, operating expenses in the Pharmaceuticals and Related Businesses and the Other Businesses

segments for the six months ended September 30, 2007 increased by ¥441 million and ¥0 million, respectively, compared with the former method, decreasing operating income in each segment by the same respective amount.

2. Segment information by geographic area

Because more than 90% of the total sales in all business segments were conducted in Japan, the disclosure of segment information by geographic area has been omitted.

3. Overseas sales

[Six months ended September 30, 2007]		(Units:	Millions of yen)
	Europe	Other	Total
I. Overseas sales	15,785	2,384	18,170
II. Consolidated net sales	_	-	104,167
III. Overseas sales as a percentage of to consolidated net sales	15.1%	2.3%	17.4%

Notes: 1. Country and regional segments are based on geographic proximity.

2. Main countries and regions included in each segment

(2) Others: North America, Asia and others

3. Overseas sales represent those of the Company and consolidated subsidiaries in countries areas outside Japan and include profit derived from licensing fees as royalty revenue.

[Six months ended September 30, 2006] (U	nits: Millions of yen)
	Total
I. Overseas sales	10,671
II. Consolidated net sales	92,154
III. Overseas sales as a percentage of to consolidated net sales	11.6%

Notes: 1. Overseas sales represent those of the Company and consolidated subsidiaries in countries and areas outside Japan and include profit derived from licensing fees as royalty revenue.

Because the overseas sales of each segment accounted for less than 10% of total consolidated sales, the disclosure of overseas sales by geographical region has been omitted.

[Year ended March 31, 2007]		(Units	s: Millions of yen)
	Europe	Other	Total
I. Overseas sales	20,404	5,658	26,063
II . Consolidated net sales	-	-	199,759
III. Overseas sales as a percentage of to consolidated net sales	10.2%	2.8%	13.0%

Notes: 1. Country and regional segments are based on geographic proximity.

2. Main countries and regions included in each segment

(1) Europe: United Kingdom, Switzerland, Germany and others

(2) Others: North America, Asia and others

3. Overseas sales represent those of the Company and consolidated subsidiaries in countries areas outside Japan and include profit derived from licensing fees as royalty revenue.

9. Notes to amounts per share

	[Six month	is ended	[Six month	is ended		
	Septemb	er 30, 2007]	September 30, 2006]		[Year endec	March 31, 2007]
Net assets per share	1,018.	49 yen	995.	78 yen	1,014.	73 yen
Earnings per share	31.	70 yen	18.	78 yen	54.	61 yen
potential shares to be	· · · ·		ential of common stock has not been p		nted since thei	e are no such
[As	s of Septer	nber 30, 2007]	[As of Septer	nber 30, 2006]	[As of Mar	ch 31, 2007]
Total net assets	346,475	million yen	339,358	million yen	345,752	million yen
Amount deducted						
from total net assets	287	million yen	268	million yen	283	million yen
(Amounts attributed to minority						
Interests in total net assets)	(287	million yen)	(268	million yen)	(283	million yen)
Net assets at period end					0.45 400	
available to common stocks	346,188	million yen	339,090	million yen	345,468	million yen
Shares outstanding as of the period end	339,902	thousands of stocks	340,526	thousands of stocks	340,452	thousands of stocks

⁽¹⁾ Europe: United Kingdom, Switzerland, Germany and others

3. Information for the computation of Earnings per share is as follows.

	[Six months ended	I [Six mont]	hs ended			
	September 3	0, 2007] Sep	tember 30, 2006]	[Year ended March 31, 2007]		
Net income	10,788 million	yen 6,394	million yen	18,594	million yen	
The amount which is not attrib	utable to					
ordinary shareholders	– million	yen –	million yen	-	million yen	
Net income related to						
common stocks	10,788 million	yen 6,394	million yen	18,594	million yen	
Average number of shares out	standing					
during the period	340,340 thousar	nds of stocks 340,558	thousands of stocks	340,519	thousands of stocks	

Interim Non-consolidated Statements of Income

(Units : Millions of yen)										
Period	Six months September 3		Six months September 3		Increase (Decrease)	Year ended Mar	ch 31, 2007			
Account	Amount	Percentage	Amount	Percentage	Amount	Amount	Percentage			
		%		%			%			
Net sales	96,253	100.0	88,021	100.0	8,232	185,686	100.0			
Cost of sales	29,631	30.8	29,337	33.3	294	59,382	32.0			
Gross profit	66,622	69.2	58,683	66.7	7,939	126,304	68.0			
Selling, general and administrative expenses	51,480	53.5	49,609	56.4	1,871	101,411	54.6			
Operating income	15,141	15.7	9,073	10.3	6,068	24,893	13.4			
Non-operating income	2,942	3.1	2,550	2.9	392	4,925	2.7			
Interest income	279		180		99	490				
Interest on securities	411		321		90	686				
Dividends income	1,001		799		202	1,125				
Real estate rent	999		960		39	1,938				
Other	250		288		(38)	684				
Non-operating expenses	2,125	2.2	1,525	1.7	600	3,833	2.1			
Interest expenses	18		15		3	33				
Contribution	529		458		71	1,245				
Depreciation	234		229		5	459				
Loss on disposal of inventories	463		-		463	930				
Loss on disposal of fixed assets	467		252		215	519				
Taxes and dues	_		156		(156)	-				
Other	412		412		0	644				
Ordinary income	15,958	16.6	10,099	11.5	5,859	25,985	14.0			
Extraordinary income	276	0.3	509	0.6	(233)	3,610	1.9			
Gain on sales of investment securities	276		-		276	65				
Gain on reversal of co-development cost of previous years	_		389		(389)	657				
Gain on sales of stocks of affiliates	_		120		(120)	120				
Gain on exchange of investment securities	_		-		_	2,765				
Extraordinary loss	1,216	1.3	386	0.5	830	386	0.2			
Loss on valuation of stocks of affiliates	1,114		-		1,114	-				
Loss on sales of stocks of affiliates	101		-		101	-				
Loss on liquidation of an investment security	-		386		(386)	386				
Income before income taxes	15,018	15.6	10,222	11.6	4,796	29,209	15.7			
Income taxes-current	3,270	3.4	1,030	1.2	2,240	7,370	4.0			
Income taxes-deferred	2,679	2.8	3,539	4.0	(860)	4,514	2.4			
Net income	9,069	9.4	5,653	6.4	3,416	17,324	9.3			

Interim Non-consolidated Balance Sheets

						(Units : N	lillions of yen)
Period	As of Septembe	er 30, 2007	As of March	31, 2007	Increase	As of Septembe	er 30, 2006
Account	Amount	Percentage	Amount	Percentage	(decrease)	Amount	Percentage
(Assets)		%		%			%
Current assets							
Cash and deposits	63,563		78,951		(15,388)	75,015	
Notes receivable-trade	203		218		(15)	199	
Accounts receivable-trade	61,486		65,258		(3,772)	61,100	
Marketable securities	17,315		4,027		13,288	4,006	
Inventories	33,020		29,945		3,075	29,198	
Other current assets	20,786		20,527		259	19,762	
Allowance for doubtful accounts	(180)		(7)		(173)	(6)	
Total current assets	196,196	48.3	198,922	47.9	(2,726)	189,276	46.4
Fixed assets							
Property, plant and equipment:							
Buildings	25,198		25,985		(787)	25,474	
Other	32,000		29,469		2,531	28,129	
Property, plant and equipment, net	57,198	14.1	55,454	13.4	1,744	53,604	13.2
Intangible fixed assets	5,729	1.4	5,757	1.4	(28)	6,195	1.5
Investments and other assets							
Investments in securities	117,217		126,187		(8,970)	131,859	
Other	29,816		28,839		977	26,750	
Allowance for doubtful accounts	(168)		(168)		0	(165)	
Total investments and other assets	146,865	36.2	154,858	37.3	(7,993)	158,444	38.9
Total fixed assets	209,793	51.7	216,070	52.1	(6,277)	218,244	53.6
Total assets	405,989	100.0	414,992	100.0	(9,003)	407,521	100.0

						(Units :	Millions of yen)
Period	As of Septembe	er 30, 2007	As of March	31, 2007	Increase	As of September 30, 2006	
Account	Amount	Percentage	Amount	Percentage	(decrease)	Amount	Percentage
(Liabilities)		%		%			%
Current liabilities:							
Accounts payable-trade	11,737		10,026		1,711	11,999	
Reserves:							
Reserve for bonuses	6,187		5,694		493	6,603	
Other reserves	985		1,018		(33)	930	
Other	17,123		24,102		(6,979)	19,022	
Total current liabilities	36,033	8.9	40,841	9.8	(4,808)	38,555	9.5
Non-current liabilities:							
Deferred tax liabilities	21,614		24,601		(2,987)	25,024	
Reserves:							
Reserve for retirement benefits	8,203		8,310		(107)	8,445	
Other reserves	168		185		(17)	185	
Other	706		706		0	706	
Total non-current liabilities	30,691	7.5	33,803	8.2	(3,112)	34,362	8.4
Total liabilities	66,725	16.4	74,645	18.0	(7,920)	72,917	17.9
(Net Assets)							
Owners' equity							
Capital stock	21,279	5.2	21,279	5.1	0	21,279	5.2
Capital surplus							
Legal capital surplus	20,227		20,227		0	20,227	
Total capital surplus	20,227	5.0	20,227	4.9	0	20,227	5.0
Retained earnings							
Legal retained earnings	5,388		5,388		0	5,388	
Others retained earnings							
Reserve for special depreciation	443		575		(132)	701	
Reserve for advanced depreciation of fixed assets	24		25		(1)	25	
General reserve	258,645		248,645		10,000	248,645	
Retained earnings brought forward	15,508		19,031		(3,523)	9,957	
Total retained earnings	280,010	69.0	273,665	65.9	6,345	264,718	65.0
Treasury stock	(10,064)	(2.5)	(9,088)	(2.2)	(976)	(8,920)	(2.2)
Total owners' equity	311,453	76.7	306,083	73.7	5,370	297,304	73.0
Valuation and translation adjustments							
Valuation difference on available-for-sale securities	27,810	6.9	34,262	8.3	(6,452)	37,298	9.1
Total valuation and translation adjustments	27,810	6.9	34,262	8.3	(6,452)	37,298	9.1
Total net assets	339,264	83.6	340,346	82.0	(1,082)	334,603	82.1
Total liabilities and net assets	405,989	100.0	414,992	100.0	(9,003)	407,521	100.0

Interim Non-consolidated Statement of Changes in Net Assets

[Six months ended September 30, 2007]

(Units : Millions of yen)

		Owners' equity								
		Capital surplus		Retained earnings						
	Capital				Other retained	d earnings			Treasury	Total
	stock	Legal capital surplus	Legal retained earnings	Reserve for special depreciation	Reserve for advanced depreciation of fixed assets	General reserve	Retained earnings brought forward	Total Retained earnings	stock	owners' equity
Balance at March 31, 2007	21,279	20,227	5,388	575	25	248,645	19,031	273,665	(9,088)	306,083
Changes of items during the period										
Reversal of reserve for special depreciation				(131)			131	_		_
Reversal of reserve for advanced depreciation of fixed assets					(0)		0	_		_
Provision of general reserve						10,000	(10,000)	_		_
Dividends from surplus							(2,723)	(2,723)		(2,723)
Net income							9,069	9,069		9,069
Purchase of treasury stock									(975)	(975)
Net changes of items other than owners' equity										
Total changes of items during the period	_	_	_	(131)	(0)	10,000	(3,522)	6,345	(975)	5,369
Balance at September 30,2007	21,279	20,227	5,388	443	24	258,645	15,508	280,010	(10,064)	311,453

	Valuation and translation adjustments	Total
	Valuation difference on available-for-sale securities	net assets
Balance at March 31, 2007	34,262	340,346
Changes of items during the period		
Reversal of reserve for special depreciation		_
Reversal of reserve for advanced depreciation of fixed assets		_
Provision of general reserve		_
Dividends from surplus		(2,723)
Net income		9,069
Purchase of treasury stock		(975)
Net changes of items other than owners' equity	(6,452)	(6,452)
Total changes of items during the period	(6,452)	(1,082)
Balance at September 30,2007	27,810	339,264

[Six months ended September 30, 2006]

(Units: Millions of yen)

	-	Owners' equity								
		Capital surplus			Retained e	earnings				
	Capital				Other retaine	d earnings			Treasury	Total
	stock	Legal capital surplus	Legal retained earnings	Reserve for special depreciation	Reserve for advanced depreciation of fixed assets	General reserve	Retained earnings brought forward	Total Retained earnings	stock	owners' equity
Balance at March 31, 2006	21,279	20,227	5,388	615	26	228,645	27,850	262,525	(8,750)	295,281
Changes of items during the period										
Provision of reserve for special depreciation *				226			(226)	_		_
Reversal of reserve for special depreciation				(140)			140	_		_
Reversal of reserve for advanced depreciation of fixed assets *					(0)		0	_		_
Reversal of reserve for advanced depreciation of fixed assets					(0)		0	_		_
Provision of general reserve *						20,000	(20,000)	_		-
Dividends from surplus *							(3,406)	(3,406)		(3,406)
Directors' bonuses *							(54)	(54)		(54)
Net income							5,653	5,653		5,653
Purchase of treasury stock									(170)	(170)
Net changes of items other than owners' equity										
Total changes of items during the period	_	_	_	86	(1)	20,000	(17,892)	2,192	(170)	2,022
Balance at September 30,2006	21,279	20,227	5,388	701	25	248,645	9,957	264,718	(8,920)	297,304

	Valuation and translation adjustments Valuation difference on available-for-sale securities	Total net assets
Balance at March 31, 2006	37,144	332,426
Changes of items during the period		
Provision of reserve for special depreciation *		-
Reversal of reserve for special depreciation		_
Reversal of reserve for advanced depreciation of fixed assets *		_
Reversal of reserve for advanced depreciation of fixed assets		_
Provision of general reserve *		_
Dividends from surplus *		(3,406)
Directors' bonuses *		(54)
Net income		5,653
Purchase of treasury stock		(170)
Net changes of items other than owners' equity	154	154
Total changes of items during the period	154	2,177
Balance at September 30,2006	37,298	334,603

* Item for appropriation of unappropriated retained earnings at the Annual General Meeting of Shareholders held in June 2006.

[Year ended March 31,2007]

(Units : Millions of yen)

		Owners' equity								
		Capital surplus			Retained e	arnings				
	Capital				Other retained	d earnings			Treasury	Total
	stock	Legal capital surplus	Legal retained earnings	Reserve for special depreciation	Reserve for advanced depreciation of fixed assets	General reserve	Retained earnings brought forward	Total Retained earnings	stock	owners' equity
Balance at March 31, 2006	21,279	20,227	5,388	615	26	228,645	27,850	262,525	(8,750)	295,281
Changes of items during the period										
Provision of reserve for special depreciation *				226			(226)	_		_
Reversal of reserve for special depreciation				(266)			266	_		_
Reversal of reserve for advanced depreciation of fixed assets *					(0)		0	_		_
Reversal of reserve for advanced depreciation of fixed assets					(0)		0	_		_
Provision of general reserve *						20,000	(20,000)	_		_
Dividends from surplus *							(3,406)	(3,406)		(3,406)
Dividends from surplus							(2,724)	(2,724)		(2,724)
Directors' bonuses *							(54)	(54)		(54)
Net income							17,324	17,324		17,324
Purchase of treasury stock									(337)	(337)
Net changes of items other than owners' equity										
Total changes of items during the period	_	_	_	(39)	(1)	20,000	(8,819)	11,139	(337)	10,802
Balance at March 31,2007	21,279	20,227	5,388	575	25	248,645	19,031	273,665	(9,088)	306,083

	Valuation and translation adjustments	Total
	Valuation difference on available-for-sale securities	net assets
Balance at March 31, 2006	37,144	332,426
Changes of items during the period		
Provision of reserve for special depreciation *		_
Reversal of reserve for special depreciation		_
Reversal of reserve for advanced depreciation of fixed assets *		_
Reversal of reserve for advanced depreciation of fixed assets		_
Provision of general reserve *		_
Dividends from surplus *		(3,406)
Dividends from surplus		(2,724)
Directors' bonuses *		(54)
Net income		17,324
Purchase of treasury stock		(337)
Net changes of items other than owners' equity	(2,881)	(2,881)
Total changes of items during the period	(2,881)	7,920
Balance at March 31,2007	34,262	340,346

* Item for appropriation of unappropriated retained earnings at the Annual General Meeting of Shareholders held in June 2006.

Significant accounting policies

1. Basis and method of securities evaluation (1) Held-to-maturity securities Amortized cost method (2) Investments in subsidiaries and affiliates At cost determined by the moving average method (3) Other securities 1. Market value available At fair value, based on market price or other appropriate quotation as of period end (Unrealized gain is charged directly to net assets; cost of sales is accounted for by the moving average method.) 2. Market value not available At cost determined by the moving average method (The securities based on Financial Products Exchange Law article 2.2 are evaluated their net profit/loss(equity method).) 2. Basis and method of inventories evaluation (1) Merchandise, raw materials At the lower-of-cost-or-market method determined by the average method. (2) Finished goods, semi-finished goods, work in process and supplies At cost determined by the average method 3. Depreciation method of fixed assets (1) Property, plant and equipment By the declining-balance method Buildings (except for structures attached to the buildings) acquired subsequent to April 1, 1998 are depreciated by straight-line method. The useful lives are as follows: Buildings and structures: 3 to 60 years Machinery and equipment and vehicles: 4 to 17 years [Change of accounting policy]

In accordance with revisions to the Corporation Tax Law, for depreciation of tangible fixed assets acquired from April 1, 2007, the Company has changed to a calculation method based on the revised Corporation Tax Law.

As a result, in the six months ended September 30, 2007, operating income, ordinary income and income before income taxes each decreased by ¥93 million compared with the former method.

[Additional information]

In accordance with revisions to the Corporation Tax Law, the Company depreciates tangible assets acquired before April 1, 2007 until the remaining value of assets reaches 5 percent of acquisition cost, as per pre-revision rules. Thereafter, the difference between the equivalent of 5 percent of the acquisition cost and the disposal cost is depreciated uniformly over five years as part of depreciation expenses.

As a result, in the six months ended September 30, 2007, operating income, ordinary income and income before income taxes each decreased by ¥425 million compared with the former method.

(2) Intangible fixed assets

Straight-line method

Expenditures relating to computer software intended for internal use are amortized over the useful life of the respective assets (in general, 5 years).

4. Basis for providing allowances and reserves

(1) Allowance for doubtful accounts

The allowance for doubtful accounts is provided to cover bad debt loss. The amount provided for general receivables is based on the historical rate of bad debts; for certain receivable accounts of considerable risk, the estimated uncollectible amount is provided as an additional allowance after examining specific possibility of collection.

(2) Reserve for bonuses

To prepare for payment of bonuses to employees, a reserve for bonuses is provided based on the estimated amount of bonuses to be paid.

(3) Reserve for retirement benefits

To prepare for the payment of retirement benefits to employees, a reserve for retirement benefits is provided based on the retirement benefit liabilities accrued and the expected value of the pension plan assets as of the period end.

Prior service cost is amortized by the straight-line method over 10 years, which is within the estimated average remaining years of service of the eligible employees.

Actuarial gain or loss is proportionally amortized in the each year following year in which the gain or loss is recognized, principally by the straight-line method over 10 years, which is within the estimated average remaining years of service of the eligible employees.

5. Transactions denominated in foreign currencies

Monetary receivables and payable denominated in foreign currencies are translated into Japanese yen at the rate of exchange in effect at the balance sheet date. Gain or loss resulting from translation is credited or charged to income.

6. Accounting for lease transactions

Finance leases other than those under which the leased property is deemed transferred to the lessee are accounted for as operating leases.

7. Hedge accounting

(1) Method of hedge accounting

Gain (loss) resulting from forward foreign exchange contracts relating to transactions denominated in a foreign currency is allocated over the applicable periods.

- (2) Hedging instruments and hedged items
 - 1. Hedging instruments
 - Forward foreign exchange contracts

2. Hedged items

Receivables and payables denominated in foreign currencies

(3) Hedging policy

The Company enters into forward foreign exchange contracts to hedge against the risk of exchange rate fluctuation for receivables and payables denominated in foreign currencies.

8. Other significant accounting policies

Consumption tax

Amounts reflected in the non-consolidated financial statements are stated exclusive of consumption tax.

[Change in method of presentation]

In accordance with amendments to the Guidelines to Regulations Governing Interim Financial Statements specifying that certificates of deposit (domestic) are to be included in securities, from the six months ended September 30, 2007, certificates of deposit (domestic) included in cash and deposits prior to April 1, 2007 are reported as marketable securities.

Furthermore, interest on certificates of deposit (domestic), included in interest income prior to April 1, 2007, is now reported as interest on securities.

Certificates of deposit (domestic) included in marketable securities as of September 30, 2007 totaled ¥13,300 million. Certificates of deposit (domestic) included in cash and deposits as of September 30, 2006 totaled ¥2,300 million.

Furthermore, interest on certificates of deposit (domestic) included in interest on securities for the six months ended September 30, 2007 totaled ¥54 million. Interest on certificates of deposit (domestic) included in interest income for the six months ended September 30, 2006 totaled ¥2 million.

Notes to interim non-consolidated financial statements

1. Notes to interim non-consolidated statements of income

	[Six months ended	[Six months ended	
	September 30, 2007]	September 30, 2006]	[Year ended March 31, 2007]
1. The major items and amounts ir	cluded in selling, general	and administrative expenses we	ere as follows:
Advertising	2,167 Million yen	2,403 Million yen	4,948 Million yen
Sales promotional activities	6,657	5,653	12,922
Salaries	7,670	7,861	19,046
Provision for reserve			
for bonuses	3,329	3,579	3,073
Retirement benefit expenses	11	121	238
R & D expenses (R&D expenses above inc	19,568 lude following amounts pro	17,865 ovided as reserves and retirement t	37,409 penefit expenses)
Provision for reserve	J		/
for bonuses	1,787 Million yen	1,862 Million yen	1,572 Million yen
Retirement benefit expenses	15	69	138
2. Depreciation for the period			
Property, plant and equipment	3,377 Million yen	2,760 Million yen	5,984 Million yen
Intangible fixed assets	820	919	1,814

2. Notes to interim non-consolidated balance sheet

	[As of September 30, 2007]	[As of March 31, 2007]	[As of September 30, 2006]
1. Accumulated depreciation of			
property, plant and equipment	154,305 Million yen	153,518 Million yen	152,013 Million yen

2. Commitments - Lines of credit The Company entered into line-of-credit commitments with 11 financial institutions in order to enhance its working capital efficiency.

Total amount of lines of credit	24,000 Million yen	24,000 Million yen	24,000 Million yen
The amount of borrowing			
Outstanding balances	24,000 Million yen	24,000 Million yen	24,000 Million yen
3. Guaranteed liabilities	80 Million yen	93 Million yen	102 Million yen

4. Accounting for settlement of notes receivable and payable.

In general, the settlement of notes is recorded on the clearing date. Though September 30, 2006, March 31, 2007 and September 30, 2007 each fell on a bank holiday, the balances of notes receivable and payable as of the end of each period include no notes which matured but were not settled on those days.

5. Consumption tax

Consumption tax paid and consumption tax received are netted and the amount is included in 'other' of current liabilities.

3. Notes to interim non-consolidated statement of changes in net assets

[Six months ended September 30, 2007] Type and number of shares of treasury stock (Units: Shares) March 31, 2007 September 30, 2007 Increase Decrease Treasury stock Common stock 10,683,759 550,056 11,233,815 10,683,759 550,056 11,233,815 Total

Note: The increase of 550,056 shares of treasury stock in common stock consists of a purchase of 50,056 odd-lot shares and a purchase of 500,000 shares approved by a resolution of the Board of Directors.

[Six months ended September 30, 2006]

Type and number of shares	of treasury stock			(Units: Shares)
	March 31, 2006	Increase	Decrease	September 30, 2006
Treasury stock				
Common stock	10,526,605	83,182	_	10,609,787
Total	10,526,605	83,182	_	10,609,787

Note: The increase in treasury stock reflects the purchase of odd-lot shares.

[Year ended March 31, 2007]

Т	ype and number of shares	of treasury stock			(Units: Shares)
		March 31, 2006	Increase	Decrease	March 31, 2007
	Treasury stock				
	Common stock	10,526,605	157,154	_	10,683,759
	Total	10,526,605	157,154	_	10,683,759

Note: The increase in treasury stock reflects the purchase of odd-lot shares.

4. Notes to lease transactions

Finance leases other than those under which the leased property is deemed transferred to the lessee:

[S	x months	ended	[Six mor	oths ended		
	Septemb	er 30, 2007]	Septerr	ber 30, 2006]	[Year ended Ma	rch 31, 2007]
(1) Acquisition cost equivalent, accumulate	d deprec	iation equivalent a	and period end bal	ance equivalent of	f leased properties	
Acquisition cost equivalent	1,319	Million yen	1,265	Million yen	1,256	Million yen
Accumulated depreciation equivalent	496		336		203	
Period-end balance	823	Million yen	929	Million yen	1,052	Million yen
Note: Tool and furniture account for most of	the above	e balances.				
(2) Breakdown of period end balance equiv Within one year	alent of 327	unexpired leases Million yen	308	Million yen	301	Million yen
Exceeding one year	495		620		750	<u>.</u>
Total	823	Million yen	929	Million yen	1,052	Million yen
(3) Lease payments and depreciation equiv					1-0	
Lease payments		Million yen	308	Million yen	152	Million yen
Depreciation equivalent	164	Million yen	308	Million yen	152	Million yen

(4) Calculation of depreciation equivalent

The lease period is deemed as the useful life of the leased property. The acquisition cost equivalent is depreciated by the straight-line method over the useful life, assuming a nil residual value.

Note: The amounts shown in 1 and 2 above include the interest portion.

[Impairment loss]

Impairment loss has not been allocated to leased assets.

5. Notes to securities

The market value of investments in subsidiaries and affiliates was not determinable at September 30, 2007.

6. Notes to amounts per share

	Six months	ended	[Six months e	ended		
	Septemb	er 30, 2007]	Septemb	er 30, 2006]	[Year endeo	March 31, 2007]
Net assets per share	998.	12 yen	982.	61 yen	999.	69 yen
Earnings per share	26.	65yen	16.	60 yen	50.	88 yen
Notes: 1. Net income after giving potential shares to be is	sued.			nas not been presente	d since there	are no such
2. Information for the comp						
	As of Septer	nber 30, 2007]	[As of Septer	nber 30, 2006]		ch 31, 2007]
Total net assets	339,264	million yen	334,603	million yen	340,346	million yen
Amount deducted from						
total net assets	-	million yen	-	million yen	-	million yen
Net assets at the period end						
available to common stocks	339,264	million yen	334,603	million yen	340,346	million yen
Shares outstanding as of						
the period end	339,902	thousands of stocks	340,526	thousands of stocks	340,452	thousands of stocks
3. Information for the comp	outation of Ea	arnings per share is a	as follows.			
	Six months	ended	[Six months	ended		
	Septe	mber 30, 2007]	Sept	ember 30, 2006]	[Year endec	March 31, 2007]
Net income	9,069	million yen	5,653	million yen	17,324	million yen
The amount which is not attri	butable to					
ordinary shareholders	—	million yen	-	million yen	-	million yen
Net income related to						
common stocks	9,069	million yen	5,653	million yen	17,324	million yen
Average number of shares ou	ıtstanding					
during the period	340,340	thousands of stocks	340,558	thousands of stocks	340,519	thousands of stocks

Others

Status of Production, Orders and Sales

1. Production

The consolidated production results for each business segment for the six months ended September 30, 2007 and September 30, 2006 and the year ended March 31,2007 were as follows: .

			(Units: Millions of yen)
Business Segment	Six months ended September 30,2007	Six months ended September 30,2006	Year ended March 31,2007
Pharmaceuticals and related businesses	69,042	75,384	145,184
Ethical drugs	61,671	68,131	132,373
Contract manufacturing	2,674	1,656	3,344
OTC drugs	3,280	3,656	6,382
Diagnostics	1,417	1,941	3,085
Other businesses	-	-	_
Total	69,042	75,384	145,184

Notes: 1. Amounts are calculated based on net sales prices.

2. Amounts are stated exclusive of consumption tax.

2. Purchases

The consolidated purchases for each business segment for the six months ended September 30, 2007 and September 30, 2006 and the year ended March 31, 2007 were as follows: (Linits: millions of ven)

				(Units: millions of yen)
Business Segment		Six months ended Six months ended September 30,2007 September 30,2006		Year ended March 31,2007
Pharmaceuticals and related businesses		8,106	9,550	18,786
	Ethical drugs	7,857	9,254	18,004
	OTC drugs	12	14	26
	Diagnostics	237	282	756
Othe	r businesses	-	-	_
Total		8,106	9,550	18,786

1. Amounts are based on actual purchases. Notes:

2. Amounts are stated exclusive of consumption tax.

3. Orders

The Shionogi Group companies manufacture products in accordance with their production plan which, in turn, is based on the sales plan. Certain consolidated subsidiaries manufacture products upon receipt of orders from customers, but these order amounts and balances do not significantly affect the Group's overall results.

4. Sales

The consolidated sales results for each business segment for the six months ended September 30, 2007 and September 30, 2006 and the year ended March 31, 2007 were as follows:

			(Units: millions of yen
Business Segment	Six months ended September 30,2007	Six months ended September 30,2006	Year ended March 31,2007
Pharmaceuticals and related businesses	99,892	90,875	191,914
Ethical drugs	77,151	76,097	157,187
Contract manufacturing	2,665	1,688	4,003
OTC drugs	2,900	3,094	6,131
Diagnostics	1,700	1,681	3,331
License fee as royalty income	15,473	8,315	21,262
Other businesses	4,275	1,279	7,844
Total	104,167	92,154	199,759
Notes: 1. Amounts are sales to customers of	outside the Shionogi Gro	bup.	•

1. Amounts are sales to customers outside the Shionogi Group.

2. Amounts are stated exclusive of consumption tax.